11/26
07:03 am
legn
Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
01:53 pm
legn
Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
08:51 am
legn
William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns [Yahoo! Finance]
Low
Report
William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns [Yahoo! Finance]
11/22
07:28 am
legn
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
Medium
Report
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
11/21
05:32 pm
legn
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
Medium
Report
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
11/19
06:45 am
legn
Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia
Medium
Report
Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia
11/14
10:23 am
legn
LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
Low
Report
LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
11/13
04:04 pm
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Barclays PLC from $94.00 to $90.00. They now have an "overweight" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Barclays PLC from $94.00 to $90.00. They now have an "overweight" rating on the stock.
11/13
12:56 pm
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Royal Bank Of Canada from $75.00 to $74.00. They now have an "outperform" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at Royal Bank Of Canada from $75.00 to $74.00. They now have an "outperform" rating on the stock.
11/13
12:36 pm
legn
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia [Yahoo! Finance]
Low
Report
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia [Yahoo! Finance]
11/13
12:08 pm
legn
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Low
Report
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
11/13
09:36 am
legn
Legend Biotech (NASDAQ:LEGN) had its price target raised by analysts at Cantor Fitzgerald from $66.00 to $75.00. They now have an "overweight" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target raised by analysts at Cantor Fitzgerald from $66.00 to $75.00. They now have an "overweight" rating on the stock.
11/12
12:54 pm
legn
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
08:21 am
legn
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights [Yahoo! Finance]
Medium
Report
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights [Yahoo! Finance]
11/12
07:06 am
legn
Legend Biotech Non-GAAP EPS of -$0.05 beats by $0.07, revenue of $272.33M misses by $3.07M [Seeking Alpha]
Medium
Report
Legend Biotech Non-GAAP EPS of -$0.05 beats by $0.07, revenue of $272.33M misses by $3.07M [Seeking Alpha]
11/12
07:00 am
legn
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
Low
Report
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
11/4
06:20 am
legn
Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Low
Report
Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
11/4
06:20 am
legn
Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Low
Report
Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
11/3
11:05 am
legn
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Low
Report
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
10/29
08:00 am
legn
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
Low
Report
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
10/20
07:43 am
legn
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
Low
Report
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
10/17
08:12 am
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $75.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $75.00 to $60.00. They now have a "buy" rating on the stock.
10/17
08:06 am
legn
Legend Biotech (NASDAQ:LEGN) was given a new $60.00 price target on by analysts at Johnson Rice.
Low
Report
Legend Biotech (NASDAQ:LEGN) was given a new $60.00 price target on by analysts at Johnson Rice.
10/15
01:35 am
legn
Legend Biotech (NasdaqGS:LEGN): A Fresh Look at Valuation Following This Week's Share Price Rebound [Yahoo! Finance]
Low
Report
Legend Biotech (NasdaqGS:LEGN): A Fresh Look at Valuation Following This Week's Share Price Rebound [Yahoo! Finance]
10/9
09:50 am
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $76.00. They now have an "overweight" rating on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $76.00. They now have an "overweight" rating on the stock.